GW‑501516 (Cardarine)
Experimental “exercise mimic” compound that caused tumors in rats; no safe way of using it in humans is known, banned in sport.


The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is GW-501516 (Cardarine)?
GW-501516 (Cardarine) is an experimental compound that the drug company GlaxoSmithKline developed to treat high blood fat levels and metabolic problems. It is not a steroid and does not act on the male hormone receptor. It has never been approved as a medicine anywhere; it is sold on the black market as a research chemical, and it has been banned on the anti-doping list since 2009.
In muscle it switches on a receptor that regulates metabolism, so more fat and sugar are burned; in mice this improved endurance even without training, which is why it is called an “exercise mimic”. The development was halted in 2007 because, in a long-term study in rats, tumors formed in several tissues, for example the intestine and the liver. So far only early studies have been done in humans, there is no long-term data, and no safe way of using it is known; it is contraindicated in cancer, liver disease and pregnancy. The contents of black-market products often do not match the label.
Mechanism
PPARδ receptor activator; not a steroid, no androgen receptor action
Half-life
about 24 hours (from animal data; little human data)
Onset
Preclinical: lipid-profile shift 2-4 weeks (extrapolated from mouse model)
Legal status
FDA never approved (Phase II terminated 2007); EU EMA never approved; research-chemical underground market only. WADA S4.5 banned since 2009.
Anecdotal reports describe Cardarine as a favourite during caloric deficits at 20 mg daily: users note markedly improved endurance, steady all-day energy without spikes or crashes, better lipid profiles and noticeably easier cardio – the fatigue and "suffering" component reportedly drops so much that even cardio-averse users say they start tolerating sessions, thanks to the glycogen-sparing effect. A commonly mentioned downside is increased sweating, and the fat-loss effect only shows up alongside a caloric deficit and regular cardio; community reports often pair it with injectable L-carnitine during cuts.
The widely cited cancer concern traces back to rodent studies using very high doses for over two years; no human cancer case has been documented in the community to date – but long-term human safety data simply does not exist, so caution remains warranted.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM . AMPK and PPARdelta agonists are exercise mimetics.. Cell.
Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM . Regulation of muscle fiber type and running endurance by PPARdelta.. PLoS Biol.
Pollock CB, Rodriguez O, Martin PL, Albanese C, Li X, Kopelovich L, Glazer RI . Induction of metastatic gastric cancer by peroxisome proliferator-activated receptorδ activation.. PPAR Res.
Heald M, Cawthorne MA . Dual acting and pan-PPAR activators as potential anti-diabetic therapies.. Handb Exp Pharmacol.
WADA / USADA banlist update. . WADA prohibited list update – S4.5 hormone and metabolic modulators (GW501516 ban 2009). WADA Code 2009 amendment; USADA bulletin 2009..
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Carcinogenic potential (most serious): GSK 2-year Sprague-Dawley rat bioassay showed dose-dependent, multi-tissue tumor formation (intestine, liver, bladder, skin, tongue) at every dose tested. No human data, but this caused Phase II termination.
- Absent human safety data: the clinical program stopped in 2007, no long-term human toxicity or tumor-latency data exists. The risk-benefit ratio is clinically negative; this is a research-only chemical.
- Possible hepatic burden: due to preclinical hepatocellular tumor formation and hepatic PPARδ activation, liver enzyme (ALT/AST/GGT) elevation is plausible, though not documented in human trials.
- Increased sweating: the most commonly reported (anecdotal) non-serious complaint in user reports; community experience, not clinical evidence.
- Quality and purity risk: no pharmacy source, only a research-chemical gray market. Declared content often does not match reality (in SARM-related analogs an RCT found ~27% of products did not contain the labeled compound); contaminated batches are a real hazard.
- Sport sanction (WADA): banned since 2009 (S4.5 hormone and metabolic modulators). Accredited LC-MS/MS urine testing detects it for 2-4 weeks; a positive result means a competition ban.
Contraindications · 6
- Human consumption in general: due to the 2-year multi-tissue rat carcinogenicity and the terminated clinical program there is no safe human protocol; research-only chemical. Do not use.
- Any malignancy history or active cancer: absolute contraindication due to the dose-dependent preclinical tumor formation.
- Pre-existing liver disease: absolute contraindication due to preclinical hepatocellular tumor formation and hepatic PPARδ activation.
- Pregnancy and breastfeeding: no human reproductive safety data; contraindicated due to the carcinogenic signal and risk to the developing organism.
- Competitive athletes (in- and out-of-competition): WADA S4.5 banned substance since 2009, detectable by accredited urine testing.
- Concurrent alcohol or other hepatotoxic agents (e.g. oral 17-alpha-alkylated steroids): hepatic stress is additive, to be avoided.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
AMPK and PPARdelta agonists are exercise mimetics.
Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM
Regulation of muscle fiber type and running endurance by PPARdelta.
Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM
Induction of metastatic gastric cancer by peroxisome proliferator-activated receptorδ activation.
Pollock CB, Rodriguez O, Martin PL, Albanese C, Li X, Kopelovich L, Glazer RI
Dual acting and pan-PPAR activators as potential anti-diabetic therapies.
Heald M, Cawthorne MA
WADA prohibited list update – S4.5 hormone and metabolic modulators (GW501516 ban 2009)
WADA / USADA banlist update.
Telegram
Have a question about GW‑501516 (Cardarine)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.